MannKind Corp. Stock
MannKind Corp. Stock
The MannKind Corp. stock is trending slightly upwards today, with an increase of €0.005 (0.190%) compared to yesterday's price.
With 24 Buy predictions and not a single Sell prediction MannKind Corp. is an absolute favorite of our community.
With a target price of 8 € there is potential for a 207.57% increase which would mean more than doubling the current price of 2.6 € for MannKind Corp..
So far the community has only identified positive things for MannKind Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of MannKind Corp. in the next few years
Pros
?
B****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of MannKind Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| MannKind Corp. | 0.190% | -45.105% | -49.038% | -49.514% | -47.364% | -42.731% | -17.587% |
| Heron Therapeutics Inc. | -0.780% | 0.690% | -13.021% | -56.987% | -8.259% | -53.119% | -93.017% |
| Evolus Inc | -2.170% | -2.747% | -14.078% | -72.977% | -35.046% | -57.091% | -66.477% |
| Sangamo Therapeutics Inc. | -2.330% | 10.544% | -23.168% | -62.173% | 5.803% | -86.723% | -96.148% |
Comments
MannKind (MNKD) had its price target lowered by Wells Fargo & Company from $8.00 to $7.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for MNKD provided by MarketBeat
MannKind (MNKD) had its "buy" rating reaffirmed by HC Wainwright. They now have a $11.00 price target on the stock.
Show more
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Show more
Ratings data for MNKD provided by MarketBeat
News
Why MannKind Stock Tumbled on Thursday
MannKind (NASDAQ: MNKD) was a stock to avoid on the second-to-last trading day of the week. Investors eagerly sold out of the commercial-stage biotech's equity, as they clearly felt its latest
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares?
On Dec. 17, 2025, Michael Castagna, Chief Executive Officer of MannKind Corporation (NASDAQ:MNKD), executed an exercise and immediate sale of 65,804 common shares for a transaction value of